AbbVie Inc. is 237.7x more valuable than RAPT Therapeutics, Inc. by market capitalization ($399.47 B vs $1.68 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | RAPT | ABBV |
|---|---|---|
| Market cap | $1.68 B | $399.47 B |
| US-listed rank | #2237 | #28 |
| Revenue (latest FY) | $0.00 | $61.16B |
| Net income (latest FY) | -$129.87M | $4.23B |
| Net margin | - | 6.9% |
| P/E (trailing FY) | - | 94.5 |
| SEC filings | 569 | 1,008 |
AbbVie Inc. is 237.7x more valuable than RAPT Therapeutics, Inc. by market capitalization ($399.47 B vs $1.68 B).
In their latest fiscal years, RAPT Therapeutics, Inc. reported $0.00 in revenue while AbbVie Inc. reported $61.16B.
Full pages: RAPT Therapeutics, Inc. and AbbVie Inc., or browse the full rankings.